Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1

Patrick A. Mayes, Nathan G. Dolloff, Colin J. Daniel, J. Judy Liu, Lori S. Hart, Kageaki Kuribayashi, Joshua E. Allen, David I.H. Jee, Jay F. Dorsey, Yingqiu Y. Liu, David T. Dicker, J. Martin Brown, Emma E. Furth, Peter S. Klein, Rosalie C. Sears, Wafik S. El-Deiry

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Tumor hypoxia is an inherent impediment to cancer treatment that is both clinically significant and problematic. In this study, we conducted a cell-based screen to identify small molecules that could reverse the apoptotic resistance of hypoxic cancer cells. Among the compounds, we identified were a structurally related group that sensitized hypoxic cancer cells to apoptosis by inhibiting the kinases GSK-3β and cyclin-dependent kinase (CDK) 1. Combinatorial inhibition of these proteins in hypoxic cancer cells and tumors increased levels of c-Myc and decreased expression of c-IAP2 and the central hypoxia response regulator hypoxia-inducible factor (HIF) 1α. In mice, these compounds augmented the hypoxic tumor cell death induced by cytotoxic chemotherapy, blocking angiogenesis and tumor growth. Taken together, our findings suggest that combinatorial inhibition of GSK-3β and CDK1 augment the apoptotic sensitivity of hypoxic tumors, and they offer preclinical validation of a novel and readily translatable strategy to improve cancer therapy.

Original languageEnglish (US)
Pages (from-to)5265-5275
Number of pages11
JournalCancer Research
Issue number15
StatePublished - Aug 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1'. Together they form a unique fingerprint.

Cite this